05.27.2020

Latest news

  • Recommendations for Blood Establishments Regarding the Novel Coronavirus Disease (COVID-19) Outbreak (v1.0)

    Recommendations for Blood Establishments Regarding the Novel Coronavirus Disease (COVID-19) Outbreak (v1.0)

     

    In order to counteract the outbreak of Novel Coronavirus Disease (COVID-19), many emergency measures have been taken all around the country. Blood establishments as well have made their best to ensure clinical blood supply. Considering the difficulties brought by the epidemic in blood collection, blood inventory management and material management, CSBT has collected multiple measures and strategies from domestic blood establishments for your reference.

    These measures and strategies generated from practical experiences are not mandatory. Each blood establishment may set procedures according to quality management specifications and your own situation.

    If you find anything inappropriate or have any other suggestions, please contact with CSBT secretariat in time so that we can continually make adjustment and issue the updated edition.

    During this special period, let’s make our efforts together to ensure blood safety and balance blood collection and supply, to serve our blood donors, volunteers and patients, and do our best to enhance occupational protection for the safety of our staff.


    1. Consultation and Evaluation of Blood Donors

    1.1 Additional inquiries about COVID-19 are suggested to evaluate blood donors. A prospective donor meets any one of the following criteria is suggested to defer blood donation for at least 28 days (4 weeks) [1]:

    a. has a fever or symptoms of respiratory illness [2];

    b. has close contact exposure to individuals who have a fever or symptoms of respiratory illness;

    c. has close contact exposure to or has a history of epidemiological association to someone confirmed as COVID-19 or clustering infected ones;

    d. has direct contact with wild animals.

    If blood donations are performed in regions apart from outbreak area like Hubei province or area with sustained local outbreaks, proceed consultation and evaluation for criteria e and f.

    e. has a history of residence in or travel from Hubei province or community with COVID-19 case report;

    f. has close contact exposure to people coming from Hubei province or people from community with COVID-19 case report.

    Notes

    [1] Current estimates of incubation period for COVID-19 range from 1 to 14 days, with median estimates of 3 to 7 days. According to the information we collected, there have been two criteria used by blood establishments, 28 days (4 weeks) and 14 days (2 weeks), for deferral of suspected prospective donor in the additional inquiry about COVID-19. Considering the epidemic situation differs in vast China, we suggest that blood establishments may set a proper deferral according to your local circumstances. In this recommendation, only one deferral (e.g.,28 days) is adopted for conciseness.

    [2] When evaluating a donor, it is suggested to differ common symptoms such as occasional cough from that of respiratory illness.

    1.2 Blood establishments may consider screening for COVID-19 markers during the epidemic period, with conditions of regulatory permission and technical availabilities.


    2. Notification from Blood Donors

    2.1 Blood establishments should provide printed instructions to educate blood donors to agree and sign, and promise to inform the blood establishment within 14 days after donation if they have symptoms of COVID-19, such as fever, cough, fatigue and shortness of breath, or been quarantined.

    2.2 Blood establishments should arrange follow up calls to donors to learn their health status after donation, and reiterate the instructions above.

    2.3 Special departments should be arranged to receive and record notifications from blood donors.

    2.4 If a blood donor after donation reports the blood establishment his/her COVID-19 alike symptoms or that he/she has been quarantined, it is suggested:

    a. to quarantine his/her blood and blood components in the bank;

    b. to retrieve his/her blood and blood components from clinical facilities, if they have been transferred there but haven’t been transfused, then quarantine them;

    c. to arrange a quarantine of the staff exposed to the donor;

    d. to follow up on donor after quarantine, and release his/her blood and blood components if he/she is excluded from infection. 

    2.5 If a donor reports his/her diagnosis of COVID-19, it is suggested:

    a. to confidentially dispose of his/her blood and blood components;

    b. to retrieve his/her blood and blood components from clinical facilities, if they have been transferred there but haven’t been transfused, then dispose of them; report to health authorities;

    c. to arrange a quarantine of the staff exposed to the donor.

    2.6 If a donor reports his/her symptoms or diagnosis of COVID-19 when his/her blood and blood components have been transfused, immediately inform the related hospital and report to health authorities.

    2.7 In outbreak areas, in parallel to routine blood screening and processing, it is recommended to quarantine blood and blood components for 14 days whenever possible. Up on quarantine is over and no abnormal notification from donors, blood and blood components could be released.


    3. Blood Donor Recruitment and Services

    3.1 Properly arrange group donations and reserved donations to make donors donate in different time period and avoid gathering. Minimize the number of accompanying persons in group blood donation.

    3.2 Every blood donor entering the blood donation site should wear a mask and be provided with hand disinfectant.

    3.3 Retain one meter or further between donors while donations if possible, or use collection bench with interval one when necessary.

    3.4 The reusable squeeze ball should be covered with disposable pad and sanitized frequently.

    3.5 Blood establishments may designate vehicles to pickup and deliver blood donors if necessary.

    3.6 Blood establishments may update guidelines on contingency blood donor recruitment, encouraging recruitment through SMS, phone calls, web.

    3.7 Blood establishments may make full use of official websites, social media, LED screens and outdoor exhibition boards at all donation sites to publicize knowledge of voluntary blood donation as well as that of prevention measures of COVID-19 so as to dispel people’s doubts and worries.

    3.8 Blood establishments may put forward proposals through various means and media to encourage celebrities, elites, civilians, military services, students to donate blood.

    3.9 If there are difficulties in parking of blood drive vehicles or accessing to campus and sites for group donations, traffic restrictions for blood delivery and blood donor pick-up, request for coordination and supports to relevant administrative departments or epidemic management departments in time. It is preferred to acquire written or printed documents or notifications, so as to facilitate on-site explanation and consultation.

    3.9 Temporarily reduce the participation of social volunteers in blood collection and supply services. If it is necessary, the requirements for epidemic prevention and personnel self-protection shall be carefully publicized, arranged, and strictly implemented and inspected.

     

    4. Balance of Blood Supply and Demand

    4.1 Contact the hospital frequently to know the demand fluctuation of blood, so as to predict the collection and demand of each blood components and formulate plans for blood collection and distribution.

    4.2 If necessary,

    a. Coordinate with blood establishments in other locations via administration departments, and plan for blood dispatch when necessary;

    b. Organize emergency blood donation;

    c. Issue a warning of blood shortage to the hospital;

    d. Suggest a suspension of elective surgery, etc. 

     

    5. Site Disinfection & Distribution and Management of Protective Articles

    5.1 Minimize the use of central air conditioning. If it is necessary to use, switch to fresh air mode. Disinfect air outlets at densely populated places after work each day.

    5.2 Ensure that air conditioning intakes adequate fresh air and exhausts directly to the outside. Turn off the return air vent when air-conditioning is not used.

    5.3 The room temperature of blood donation sites should be controlled at around 26'C. Ventilate the air at least twice a day for not less than 30 minutes each time. Wipe seats, stairs, escalator handrails, workbenches, floors and instruments with chlorine disinfectant or 75% alcohol before and after work.

    5.4 Enhance the disinfection of blood delivery vehicles. Disinfect after each trip, especially the steering wheels, door handles and seats.

    5.5 Enhance the disinfection of blood transport boxes. Disinfect both the inside and the outside of the boxes after they are returned from hospital to blood establishment each day.

    5.6 Treat routine medical waste as usual. Emergency treatment should be carried out to deal with contamination of blood, secretions or vomit of individuals diagnosed with or suspected of COVID-19.

    5.7 Each department does not keep inventory of vital protective articles, which are uniformly managed by the blood establishment. Each department need to apply for them on demand every day.

     

    6. Supplement

    6.1 Arrange the staff in different shifts and one shift each day to complete the workload of the department. Minimize contacts and meeting between members of different shifts.

    6.2 Do disinfect handover areas, instruments, documents and records, etc.

    6.3 Enhance daily monitoring of health status including body temperature of all the staffs, including logistic and canteen staffs. If anyone has a fever or symptoms of COVID-19, timely self-quarantine and go for a medical treatment.

    6.4 Staff should try to work in the vicinity of their posts to avoid unnecessary walking. Department should keep accurate attendance records, so as to track people in time and minimize influence when the abnormal makes it necessary to an investigation or a quarantine.

    6.5 Taking records in time, including routine records and additional work records during the epidemic.

    6.6 Every department should report health status of its staff each day. If someone has a fever, take a rest at home in time. If the fever lasts for 2 days, go for a test in the authorized department. Meanwhile, close contacts should be quarantined at home till the diagnosis is clear.

    6.7 Staffs are required not to leave for another city without special reasons during the epidemic. If it is necessary, report to the leader in charge and ask for a permission, and report the details of route, people contacted, and personal health status, etc. up on returning to work.

    6.8 Disinfect elevators and public door handles once an hour.

    6.9 Fingerprint attendance system should be suspended during the epidemy.

    6.10 A series of measures are suggested to restrict public dining, such as reducing gathering, avoiding talking while dining, and different departments dine separately at different times. Make sure garbage sorting and management are implemented.


    Acknowledgements (in no particular order)

    Contributing Organizations: Shanghai Blood Center, Wuhan Blood Center, Central Blood Station of Wenzhou, Anhui Province Blood Center, Central Blood Station of Ya’an, Baoding Central Blood Bank, Ordos Central Blood Bank, Wenshan Zhuang-Miao Autonomous Prefecture Central Blood Bank, Aba Tibetan Qiang Autonomous Prefecture Central Blood Bank, Central Blood Station of Sanmenxia, Zhoushan Central Blood Bank, Central Blood Station of Lianyungang, Central Blood Station of Guang’an, Chongqing Blood Center, Bazhong City Blood Center, Guangzhou Blood Center, Blood Center of Zhejiang Province, Nanning Blood Center, Ningxia Blood Center, Shanxi Province Blood Center, Central Blood Station of Baotou

     

    Drafting: ZHANG Xi, LIANG Xiaohua, QI Hai, LIU Qingning, LIN Junjie, ZHANG Yuling

    Directing: GAO Xinqiang, ZHANG Rui, ZHU Yongming, FU Yongshui

     

     

     

     

     

    Translated by ZHU Shanshan, YANG Ying, TANG Dingjie,

     CHEN Xin, ZHU Yunong, SHAO Lei, LIU Taixiang;

                   Reviewed by MA Ling, JIANG Nizhen

     

    This translation has not been reviewed

    by the taskforce drifting the Recommendation V1

    Original Document in Chinese

    https://www.csbt.org.cn/plus/view.php?aid=16530


  • The 1st China HLA Summit Forum & 2019 Annual Meeting of Working Party on Histocompatibility, CSBT is successfully held

    The 1st China HLA Summit Forum and 2019 annual meeting of Working Party on Histocompatibility, CSBT, jointly held by CSBT/HLA, China Marrow Donor Program and Beijing hospital, was successfully held in Fuzhou, Fujian Province, from September 5 to 8. More than 200 colleagues from home and abroad attended the forum.


    ZHANG Zhixin, chairman of CSBT/HLA, proposed to promote the in-depth research and extensive application of HLA, further to improve the HLA typing platelet library, and finally to start HLA selective blood transfusion. 


    More than 20 experts actively in the fields of HLA research and application at home and abroad attended the forum, including Professor GAO Xiaojiang, senior researcher of American National Institutes of Health, Professor YU Neng, director of Clinical HLA Department of American National Marrow Donor Program, Professor CHEN Ge, HLA Department of Stanford University Medical Center, Researcher JIN Yiping, Immunogenetics Center of University of California Medical School, Los Angeles, and Professor ZHANG Yanhui, director of HLA Department of Florida Children's Hospital, etc. 


    The academic exchanges mainly involved new progress and technology of HLA, such as the research on HLA and disease, HLA and transplantation, HLA and blood transfusion, HLA evolution, HLA population genetics, synergistic effect of HLA and other factors, HLA and marrow donor program, HLA and platelet donor program, HLA donor program, second generation sequencing technology, and the role of HLA antibody detection in organ and hematopoietic stem cell transplantation.

    微信图片_20191122135337.png

    Translated by LI Xueyin; 

    Reviewed by MA Ling, JIANG Nizhen


  • Academic Conference on New Progress of Blood Donor Screening Technology is held in Guangxi Province

    Academic conference on New Progress of Blood Donor Screening Technology, hosted by CSBT, and co-organized by Working Party on Transfusion Transmitted Infectious Diseases of CSBT(CSBT/TTD) and both Guangxi and Guangdong Society of Blood Transfusion, was held in Nanning, Guangxi Province on October 14. Nearly 200 participants attended the opening ceremony and the three-day training course.


    President ZHU Yongming pointed out in his speech that the course was the first academic and training activity held by CSBT/TTD. It was such a comprehensive and systematic one that it covered puzzles encountered in blood donor screening in China, the risk of blood transfusion transmitted pathogens not yet included in blood donor screening, the establishment of new blood screening technology, and new progress on blood screening technology at home and abroad, etc. All the presenters including experts who had been working in the front line and experts who were mainly engaged in theoretical and technical research were from blood establishments and clinical testing labs as well as scientific research institutions. The lectures they gave were not only omni-directional and forward-looking, but also practical. Everyone would be enlightened and harvested in this course.


    After the opening ceremony, FU Yongshui, Director of Guangzhou Blood Center,  and CHEN limin, research professor of Institute of Blood Transfusion, Chinese Academy of Medical Sciences, gave lectures on Research Progress on Hepatitis C Virus and Research Progress on Pathogenic Mechanism of Blood Transfusion Transmitted Pathogens, respectively.



     献血者技术筛查新进展.jpg

    Reported by the CSBT Secretariat

    Translated by ZHU Yunong;

    Reviewed by MA Ling, JIANG Nizhen


  • The book launch of Annual Report on Development of China Blood Transfusion Industry(2019) is held in Guizhou Province
  • The 13th Education Course for Leadership of Blood Service is held in Shanghai
  • Deputy Director of National Health of Commission, Wang Hesheng, attended the main events of World Bl
  • The 9th national congress of CSBT was held in Chongqing
  • Professor Zhu Yongming, President of CSBT, donated blood in Beijing
  • The Training Course of Continuous Promotion of Haemovigilance was successfully held in Chongqing

    The training course of continuous promotion of haemovigilance was successfully held in Chongqing from May 6 to 8, 2019.

     

    On the opening ceremony, President ZHU Yongming retrospected the development of haemovigilance over the past 17 years in China and reviewed the relevant work carried out since the establishment of the haemovigilance committee. He said that since haemovigilance was in its infancy in China, it was necessary to carry out training on relative knowledges and concepts. Since this training course covered not only standards, but also practical experience and data analysis of haemovigilance, it provided an outstanding opportunity to learn and communicate. President ZHU Yongming hoped that the knowledge and ideas learned would be applied to practical work to solve the difficulties and problems, and would promote the development of haemovigilance.

     

    During the three days of training, expert teachers had given 14 excellent lectures on specific topics including: 

    • Blood screening strategy for centralized blood supply;

    • Classification and diagnosis of adverse transfusion reaction;

    • Disposition and case analysis of adverse transfusion reaction;

    • International practice for haemovigilance and interpretation to the Organizational Standard Guideline for Haemovigilance;

    • Practice and experience of haemovigilance in Wuxi area, Jiangsu Province;

    • The construction of haemovigilance system in blood establishment;

    • Tracing of transfusion-transmitted infection;

    • Research progress and case analysis of adverse transfusion reaction; the work program on pilot haemovigilance in China;

    • Progress and application in monitoring of adverse blood donation reaction;

    • Case reports and analysis of adverse events occurred in blood establishment.

     

    During the three days of training, the trainee mastered the content comprehensively by actively participating in course learning, communicating with expert teachers, and completing the assessment exam, which fulfilled the purpose of this training course.

     图片3.png

     

    Reported by the CSBT/HV 

    Translated by LIU Taixiang;

    Reviewed by MA Ling, JIANG Nizhen

     

     


  • About CSBT